Related Experiment Video

Updated: Jun 30, 2026

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
08:02

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice

Published on: October 20, 2013

Systemic and pulmonary effects of vasopressors and inotropes in the neonate

Istvan Seri1

  • 1Department of Pediatrics, Children's Hospital Los Angeles, LAC/USC Medical Center, Keck School of Medicine, University of Southern California, Los Angeles, Calif., USA. iseri@chla.usc.edu

Biology of the Neonate
|June 14, 2006
PubMed

Insights

This review covers vasopressor-inotropes and inotropes in neonates, highlighting their hemodynamic effects. Long-term cardiovascular and neurodevelopmental outcomes remain largely unknown.

Area of Science:

  • Neonatal physiology
  • Pharmacology
  • Cardiovascular medicine

Background:

  • Vasopressor-inotropes and inotropes are commonly used in neonates.
  • Their immediate hemodynamic effects are relatively well-understood.
  • Limited data exists on long-term impacts.

Purpose of the Study:

  • To review the hemodynamic actions of common vasopressor-inotropes and inotropes in neonates.
  • To identify knowledge gaps regarding their long-term benefits.

Main Methods:

  • Literature review of systemic and pulmonary hemodynamic actions.
  • Focus on preterm and term neonates.

Main Results:

  • Common vasopressor-inotropes and inotropes exert significant hemodynamic effects.
  • Specific actions vary depending on the agent and neonatal condition.

Conclusions:

  • Current understanding of neonatal hemodynamic support is primarily based on short-term effects.
  • Further research is crucial to determine medium- and long-term cardiovascular and neurodevelopmental benefits.

More Related Videos

The Perinatal Asphyxiated Lamb Model: A Model for Newborn Resuscitation09:03

The Perinatal Asphyxiated Lamb Model: A Model for Newborn Resuscitation

Published on: August 15, 2018

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus11:59

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus

Published on: April 28, 2023

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...